---
document_datetime: 2025-12-02 05:39:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/skysona.html
document_name: skysona.html
version: success
processing_time: 0.11697
conversion_datetime: 2025-12-24 00:36:07.328845
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Skysona

[RSS](/en/individual-human-medicine.xml/67460)

##### Withdrawn

This medicine's authorisation has been withdrawn

elivaldogene autotemcel Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Skysona](#news-on)
- [More information on Skysona](#more-information-on-skysona-940)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 November 2021, the European Commission withdrew the marketing authorisation for Skysona (elivaldogene autotemcel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, bluebird bio (Netherlands) B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Skysona was granted marketing authorisation in the EU on 16 July 2021 for treatment of early cerebral adrenoleukodystrophy. No patients had been treated with Skysona since its marketing authorisation.

The European Public Assessment Report (EPAR) for Skysona is updated to indicate that the marketing authorisation is no longer valid.

Skysona : EPAR - Medicine overview

Reference Number: EMA/413176/2021

English (EN) (719.27 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/overview/skysona-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-413)

български (BG) (809.77 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/bg/documents/overview/skysona-epar-medicine-overview_bg.pdf)

español (ES) (717.73 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/es/documents/overview/skysona-epar-medicine-overview_es.pdf)

čeština (CS) (788.7 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/cs/documents/overview/skysona-epar-medicine-overview_cs.pdf)

dansk (DA) (714.49 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/da/documents/overview/skysona-epar-medicine-overview_da.pdf)

Deutsch (DE) (722.06 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/de/documents/overview/skysona-epar-medicine-overview_de.pdf)

eesti keel (ET) (709.45 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/et/documents/overview/skysona-epar-medicine-overview_et.pdf)

ελληνικά (EL) (813.98 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/el/documents/overview/skysona-epar-medicine-overview_el.pdf)

français (FR) (719.11 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fr/documents/overview/skysona-epar-medicine-overview_fr.pdf)

hrvatski (HR) (743.42 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hr/documents/overview/skysona-epar-medicine-overview_hr.pdf)

italiano (IT) (716.83 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/it/documents/overview/skysona-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (809.41 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lv/documents/overview/skysona-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (748.43 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lt/documents/overview/skysona-epar-medicine-overview_lt.pdf)

magyar (HU) (789.47 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hu/documents/overview/skysona-epar-medicine-overview_hu.pdf)

Malti (MT) (802.26 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/mt/documents/overview/skysona-epar-medicine-overview_mt.pdf)

Nederlands (NL) (716.27 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/nl/documents/overview/skysona-epar-medicine-overview_nl.pdf)

polski (PL) (797.41 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pl/documents/overview/skysona-epar-medicine-overview_pl.pdf)

português (PT) (719.47 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pt/documents/overview/skysona-epar-medicine-overview_pt.pdf)

română (RO) (749.78 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/ro/documents/overview/skysona-epar-medicine-overview_ro.pdf)

slovenčina (SK) (788.96 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sk/documents/overview/skysona-epar-medicine-overview_sk.pdf)

slovenščina (SL) (787.88 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sl/documents/overview/skysona-epar-medicine-overview_sl.pdf)

Suomi (FI) (714.38 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fi/documents/overview/skysona-epar-medicine-overview_fi.pdf)

svenska (SV) (716.09 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sv/documents/overview/skysona-epar-medicine-overview_sv.pdf)

Skysona : EPAR - Risk-management-plan summary

English (EN) (758.42 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/rmp-summary/skysona-epar-risk-management-plan-summary_en.pdf)

## Product information

Skysona : EPAR - Product information

English (EN) (1.45 MB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/product-information/skysona-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-398)

български (BG) (2.6 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/bg/documents/product-information/skysona-epar-product-information_bg.pdf)

español (ES) (1.42 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/es/documents/product-information/skysona-epar-product-information_es.pdf)

čeština (CS) (2.36 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/cs/documents/product-information/skysona-epar-product-information_cs.pdf)

dansk (DA) (1.39 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/da/documents/product-information/skysona-epar-product-information_da.pdf)

Deutsch (DE) (1.59 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/de/documents/product-information/skysona-epar-product-information_de.pdf)

eesti keel (ET) (1.36 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/et/documents/product-information/skysona-epar-product-information_et.pdf)

ελληνικά (EL) (2.63 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/el/documents/product-information/skysona-epar-product-information_el.pdf)

français (FR) (1.52 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fr/documents/product-information/skysona-epar-product-information_fr.pdf)

hrvatski (HR) (1.44 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hr/documents/product-information/skysona-epar-product-information_hr.pdf)

íslenska (IS) (1.41 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/is/documents/product-information/skysona-epar-product-information_is.pdf)

italiano (IT) (1.52 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/it/documents/product-information/skysona-epar-product-information_it.pdf)

latviešu valoda (LV) (2.3 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lv/documents/product-information/skysona-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.64 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lt/documents/product-information/skysona-epar-product-information_lt.pdf)

magyar (HU) (2.17 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hu/documents/product-information/skysona-epar-product-information_hu.pdf)

Malti (MT) (2.29 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/mt/documents/product-information/skysona-epar-product-information_mt.pdf)

Nederlands (NL) (1.56 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/nl/documents/product-information/skysona-epar-product-information_nl.pdf)

norsk (NO) (1.38 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/no/documents/product-information/skysona-epar-product-information_no.pdf)

polski (PL) (2.35 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pl/documents/product-information/skysona-epar-product-information_pl.pdf)

português (PT) (1.41 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pt/documents/product-information/skysona-epar-product-information_pt.pdf)

română (RO) (1.54 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/ro/documents/product-information/skysona-epar-product-information_ro.pdf)

slovenčina (SK) (2.22 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sk/documents/product-information/skysona-epar-product-information_sk.pdf)

slovenščina (SL) (2.19 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sl/documents/product-information/skysona-epar-product-information_sl.pdf)

Suomi (FI) (1.49 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fi/documents/product-information/skysona-epar-product-information_fi.pdf)

svenska (SV) (1.41 MB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sv/documents/product-information/skysona-epar-product-information_sv.pdf)

18/11/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Skysona : EPAR - All authorised presentations

English (EN) (659.4 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-917)

български (BG) (686.79 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/bg/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_bg.pdf)

español (ES) (658.86 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/es/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_es.pdf)

čeština (CS) (677.6 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/cs/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (665.26 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/da/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (661.44 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/de/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (657.16 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/et/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (683.93 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/el/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_el.pdf)

français (FR) (659.43 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fr/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (659.52 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hr/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (660.93 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/is/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_is.pdf)

italiano (IT) (657.56 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/it/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (677.33 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lv/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (661.7 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/lt/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (677.38 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/hu/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (679.82 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/mt/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (657.82 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/nl/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (660.61 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/no/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_no.pdf)

polski (PL) (678.57 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pl/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_pl.pdf)

português (PT) (659.12 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/pt/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_pt.pdf)

română (RO) (660.43 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/ro/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (677.66 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sk/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (675.2 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sl/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (655.9 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/fi/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (659.33 KB - PDF)

**First published:**

27/07/2021

**Last updated:**

04/04/2022

[View](/sv/documents/all-authorised-presentations/skysona-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Skysona Active substance elivaldogene autotemcel International non-proprietary name (INN) or common name elivaldogene autotemcel Therapeutic area (MeSH) Adrenoleukodystrophy Anatomical therapeutic chemical (ATC) code N07

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an ABCD1 genetic mutation, and for whom a human leukocyte antigen (HLA) matched sibling haematopoietic stem cell donor is not available.

## Authorisation details

EMA product number EMEA/H/C/003690

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

bluebird bio (Netherlands) B.V.

Stadsplateau 7

Opinion adopted 20/05/2021 Marketing authorisation issued 16/07/2021

## Assessment history

## Initial marketing authorisation documents

Skysona : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-686727

English (EN) (889.37 KB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/orphan-maintenance-report/skysona-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Skysona : EPAR - Public assessment report

Adopted

Reference Number: EMA/332184/2021

English (EN) (6 MB - PDF)

**First published:** 27/07/2021

**Last updated:** 04/04/2022

[View](/en/documents/assessment-report/skysona-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Skysona

Adopted

Reference Number: EMA/CHMP/273940/2021

English (EN) (757.04 KB - PDF)

**First published:** 21/05/2021

**Last updated:** 04/04/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-skysona_en.pdf)

#### News on Skysona

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-may-2021) 21/05/2021

[First gene therapy to treat children with rare inherited neurological disease](/en/news/first-gene-therapy-treat-children-rare-inherited-neurological-disease) 21/05/2021

#### More information on Skysona

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-12-1003) on 6 June 2012. Skysona was withdrawn from the Community register of orphan medicinal products by the European Commission in November 2021 at the time of the withdrawal of the marketing authorisation.

**This page was last updated on** 04/04/2022

## Share this page

[Back to top](#main-content)